[EN] PROCESS FOR THE PREPARATION OF AN ENDOTHELIN RECEPTOR ANTAGONIST<br/>[FR] PROCÉDÉ DE PRÉPARATION D'UN ANTAGONISTE DU RÉCEPTEUR DE L'ENDOTHÉLINE
申请人:CIPLA LTD
公开号:WO2013057468A1
公开(公告)日:2013-04-25
The present invention relates to a novel process for the preparation of a compound of formula (I) wherein R is a methyl or methoxy group; to certain novel intermediates prepared in such a process and their use.
Azinyloxy, and phenoxy-diaryl-carboxylic acid derivatives, their preparation and use as mixed ETA/ETB endothelin receptor antagonists
申请人:Abbott GmbH & Co., KG
公开号:US06670367B1
公开(公告)日:2003-12-30
The invention relates to carboxylic acid derivatives of the formula I
where the radicals have the meanings stated in the description, and to their use as drugs.
reported here the low loading porphyrin-inspired high-valent manganese (IV)-oxo complex was applied in oxidative kineticresolution (OKR) of racemic heterocyclic sulfoxides using the environmentally benign hydrogen peroxide for the first time. This approach allows for rapid OKR (0.5 h) of a variety of racemic sulfoxides (including pyridine, pyrimidine, pyrazine, thiazole, benzothiazole, thiophene) in
The present invention relates to novel butyne diol derivatives of the general formula I and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more compounds of the general formula I and especially their use as endothelin receptor antagonists.
[EN] NOVEL PYRAZOLE AND IMIDAZOLE DERIVATIVES USEFUL AS OREXIN ANTAGONISTS<br/>[FR] NOUVEAUX DÉRIVÉS DE PYRAZOLE ET D'IMIDAZOLE UTILES À TITRE D'ANTAGONISTES D'OREXINE
申请人:ACTELION PHARMACEUTICALS LTD
公开号:WO2012110986A1
公开(公告)日:2012-08-23
The present invention relates to pyrazole and imidazole derivatives of formula (I) wherein U, V, L, X, Y, R1, (R2)n and (R3)m and ring A are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as orexin receptor antagonists.